z-logo
open-access-imgOpen Access
Efficacy of Baduanjin exercise for rehabilitation after COVID-19
Author(s) -
Jian Rong,
Jing Li,
Fushi Jing,
Yonghui Ren,
Yunpeng Xiao,
Qi Pan,
Mengtian Li,
Yueming Lv,
Jing Zhang,
Fujie Jing
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000026366
Subject(s) - medicine , medline , cochrane library , rehabilitation , randomized controlled trial , meta analysis , subgroup analysis , covid-19 , physical therapy , family medicine , disease , pathology , political science , infectious disease (medical specialty) , law
Background: The study aims to evaluate the effectiveness and safety of Baduanjin exercise for rehabilitation after COVID-19. Methods: The following electronic databases will be searched from establishment to Jan 2021: Cochrane Library, MEDLINE, EMBASE, Web of Science, Springer, World Health Organization International Clinical Trials Registry Platform, China National Knowledge Infrastructure, Wan-fang database, Chinese Scientific Journal Database, Chinese Biomedical Literature Databases, and other databases, All published randomized controlled trials about this topic will be included. Two independent researchers will operate article retrieval, duplication removing, screening, quality evaluation, and data analyses by Review Manager (V.5.3.5). Meta-analyses, subgroup analysis, and/or descriptive analysis will be performed based on the included data conditions. Results: The results of this study will provide a combination of high-quality evidence for researchers in the current field of COVID-19 treatment and rehabilitation. Conclusion: The conclusion of this study will provide the evidence of whether Baduanjin is an effective and safe intervention for rehabilitation after COVID-19. PROSPERO registration number: CRD42020181078.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here